No follow-ons in April as drought crosses five-week threshold: Finance Report

For the first time in at least six years, public life sciences companies disclosed zero follow-on fundings of $25 million or more in a calendar month, according to BioCentury’s BCIQ database.

With uncertainty and volatility roiling the public markets, it has been more than five weeks since Humacyte Inc. (NASDAQ:HUMA) priced its $50 million offering on March 25. Although a handful of companies raised PIPEs above the $25 million threshold in April, no biotech has priced a follow-on since Humacyte’s...